Traditional Chinese medicine composition and traditional Chinese medicine extract for treating posterior circulation ischemic vertigo and application of traditional Chinese medicine composition and traditional Chinese medicine extract
Through the extract of traditional Chinese medicine compositions of epimedium and Chuanxiong, the high risk and inefficiency of post-circulating ischemic vertigo treatment in the prior art was solved, and the effect of improving cerebral blood flow rate and improving vertigo symptoms was achieved. Advantages of low cost and low toxic side effects.
Patent Information
- Application Number
- CN202411225390.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art has high risk and inefficiency in post-treatment of circulating ischemic vertigo, especially in the elderly population, where an efficient and low risk treatment is lacking.
The traditional Chinese medicine composition of epimedium and Chuanxiong is used to extract and concentrate under reduced pressure by heating and reflux, and traditional Chinese medicine extract is obtained, which is used to increase the cerebral blood flow rate and improve the symptoms of vertigo, and different dosage forms are prepared in combination with pharmaceutical excipients to improve the efficacy.
The traditional Chinese medicine composition effectively increases the cerebral blood flow rate of rats with posterior circulation ischemic vertigo and improves vertigo symptoms. The traditional Chinese medicine raw materials are cheap, have fewer toxic side effects, and reduces medical costs. It is active in the treatment of posterior circulation ischemic vertigo. significance.
Smart Images

Figure CN118903235A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicine, and particularly relates to a traditional Chinese medicine composition for treating posterior circulation ischemic vertigo, a traditional Chinese medicine extract and applications thereof. Background Art
[0002] With the development of society, economy and medicine, the life expectancy of the population has been significantly extended, and aging has become an important issue in my country. The great challenge associated with aging is the significant increase in the incidence and prevalence of cerebrovascular disease and cognitive impairment, which has a serious impact on patients, families and society. Posterior circulation ischemia (PCI) is a lesion caused by ischemia of the vertebral basilar artery system. It is a common ischemic cerebrovascular disease, accounting for about 20% of ischemic stroke, especially posterior circulation ischemic vertigo (PCIV), which has become a common symptom in clinical practice. Among the causes of PCIV, atherosclerosis accounts for 35%, cardioembolism accounts for 18%, small vessel disease accounts for 13%, and others account for 27%. Atherosclerosis is considered to be the main cause of PCI.
[0003] Western medicine treatment for PCIV is mainly based on the treatment of PCI, while vasodilators such as statins and calcium ion antagonists and anti-vertigo agents such as diphenhydramine and diphenidol are given for symptomatic treatment. For the acute phase of PCI, medical treatment, surgical treatment and intravascular treatment including antiplatelet drugs and anticoagulants are mainly used to improve blood supply to achieve the purpose of stopping vertigo. There is no research to confirm the clinical benefits of the above treatment methods when used in the elderly, but the risks are obvious. Therefore, there is an urgent need for an efficient and low-risk PCIV treatment method or drug. Summary of the invention
[0004] In order to obtain an efficient and low-risk PCIV therapeutic drug, the present invention provides a traditional Chinese medicine composition for treating posterior circulation ischemic vertigo. The traditional Chinese medicine composition can effectively increase the cerebral blood flow velocity of animals with posterior circulation ischemic vertigo, improve the symptoms of vertigo, and has small toxic and side effects. It is very promising in the preparation of drugs for treating posterior circulation ischemic vertigo and has positive practical significance in the field of posterior circulation ischemic vertigo treatment.
[0005] The invention also provides a traditional Chinese medicine extract for treating posterior circulation ischemic vertigo and application thereof.
[0006] The present invention is achieved through the following technical solutions:
[0007] The invention provides a traditional Chinese medicine composition for treating posterior circulation ischemic vertigo. The traditional Chinese medicine composition consists of epimedium and chuanxiong, wherein the mass ratio of epimedium to chuanxiong is 4:3.
[0008] Based on the same inventive concept, the present invention provides a Chinese medicine extract for treating posterior circulation ischemic vertigo, wherein the Chinese medicine extract is an extract of the above-mentioned Chinese medicine composition for treating posterior circulation ischemic vertigo.
[0009] Based on the same inventive concept, the present invention provides a method for preparing a Chinese medicine extract for treating posterior circulation ischemic vertigo, the preparation method comprising:
[0010] Mixing the above-mentioned Chinese medicinal composition for treating posterior circulation ischemic vertigo with water to obtain a mixture;
[0011] The mixture is subjected to heating reflux extraction and reduced pressure concentration to obtain a water extract concentrate;
[0012] The water extract concentrate is dried to obtain a Chinese medicinal extract for treating posterior circulation ischemic vertigo.
[0013] Furthermore, the aforementioned Chinese medicine composition for treating posterior circulation ischemic vertigo is mixed with water to obtain a mixture, specifically comprising:
[0014] Mixing the above-mentioned Chinese medicinal composition for treating posterior circulation ischemic vertigo with 15 times the amount of water to obtain a mixture;
[0015] The mixture is subjected to heating reflux extraction and reduced pressure concentration to obtain a water-extracted concentrated solution, which specifically comprises:
[0016] The mixture was heated and refluxed for extraction twice, each time for 1 hour, to obtain the Xingnao Fang water extract;
[0017] Concentrating the water extract of the Xingnao Recipe under reduced pressure at 50-70° C. to obtain a water extract concentrate;
[0018] Among them, the specific gravity of the water-extracted concentrate is 1.10-1.20.
[0019] Preferably, the heating and refluxing extraction of the mixture specifically comprises:
[0020] The mixture is heated to 100° C., refluxed for 1 hour, and then filtered to obtain filtrate A and medicinal residues. The same volume of water is added to the medicinal residues and then continued to be heated to 100° C., refluxed for 1 hour, and then filtered to obtain filtrate B. The filtrate A and the filtrate B are combined to obtain a water-extracted reflux liquid.
[0021] In the present invention, by maintaining the specific gravity of the water-extracted concentrate at 1.10-1.20, the degree of water-extracted concentration can be controlled so that the final concentrated solution has a consistency suitable for drying. A concentrated solution with a too thin consistency will lead to a prolonged drying time, thereby causing the loss or degradation of volatile active ingredients, and thus failing to obtain the expected efficacy.
[0022] Furthermore, the aqueous extract concentrate is dried to obtain a Chinese medicinal extract for treating posterior circulation ischemic vertigo, specifically comprising:
[0023] spray-drying the water extract concentrate to obtain a Chinese medicinal extract for treating posterior circulation ischemic vertigo;
[0024] in,
[0025] The spray drying temperature is 110-120°C.
[0026] Based on the same inventive concept, the present invention provides an application of a traditional Chinese medicine composition for treating posterior circulation ischemic vertigo in the preparation of a drug for preventing and treating posterior circulation ischemia or posterior circulation ischemic vertigo.
[0027] Based on the same inventive concept, the present invention provides an application of a traditional Chinese medicine extract for treating posterior circulation ischemic vertigo in the preparation of a drug for preventing and treating posterior circulation ischemia or posterior circulation ischemic vertigo.
[0028] Based on the same inventive concept, the present invention provides an application of a traditional Chinese medicine composition for treating posterior circulation ischemic vertigo in the preparation of a drug for preventing and treating ischemic vertigo.
[0029] Based on the same inventive concept, the present invention provides an application of a Chinese medicine extract for treating posterior circulation ischemic vertigo in the preparation of a drug for preventing and treating ischemic vertigo.
[0030] Based on the same inventive concept, the present invention also provides a drug for preventing and treating posterior circulation ischemia or posterior circulation ischemic vertigo, the active ingredients of the drug including the above-mentioned Chinese medicine composition for treating posterior circulation ischemic vertigo and / or the above-mentioned Chinese medicine extract for treating posterior circulation ischemic vertigo.
[0031] Furthermore, the drug also contains pharmaceutically acceptable excipients, and the pharmaceutical excipients include at least one of an excipient, a carrier, a binder and a lubricant.
[0032] Preferably, the pharmaceutical excipient includes at least one of dextrin, powdered sugar and starch.
[0033] Furthermore, the dosage form of the drug includes any one of granules, oral liquid, tablets and capsules.
[0034] Based on the same inventive concept, the present invention also provides a drug for preventing and treating ischemic vertigo, wherein the active ingredients of the drug include the above-mentioned Chinese medicine composition for treating posterior circulation ischemic vertigo and / or the above-mentioned Chinese medicine extract for treating posterior circulation ischemic vertigo.
[0035] Furthermore, the drug for preventing and treating ischemic vertigo includes a drug for preventing and treating cervical vertigo.
[0036] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:
[0037] 1. The present invention discloses a Chinese medicine composition for treating posterior circulation ischemic vertigo. For the first time, two herbs, Epimedium and Chuanxiong, are used together to form an independent prescription to treat posterior circulation ischemic vertigo. Epimedium is the main herb, which can warm and tonify kidney yang, tonify the kidney and replenish essence, and essence produces marrow that is passed to the brain, nourishes the brain marrow, and awakens the brain and opens the mind; Chuanxiong is the secondary herb, which is known as "blood-qi medicine", can both promote blood circulation and remove blood stasis, and can promote qi and stop bleeding, and has the effect of promoting the flow of qi and blood. Chuanxiong Shengsan can also "go up to the head" to treat the symptoms of blood stasis in the head. The two herbs are used in combination to play a synergistic role and increase the effects of "warming yang and tonifying the kidney, promoting blood circulation and removing blood stasis and unblocking meridians". They can be applied to the treatment of posterior circulation ischemic vertigo, and have positive practical significance in the field of posterior circulation ischemic vertigo treatment.
[0038] 2. The present invention discloses a Chinese medicine composition for treating posterior circulation ischemic vertigo. It is the first time to propose that Epimedium is used as the main drug and Ligusticum chuanxiong is used as the auxiliary drug for the treatment of posterior circulation ischemic vertigo. The extract of the Chinese medicine composition is used to intervene in rats with posterior circulation ischemic vertigo, which can effectively increase the cerebral blood flow in the ischemic area of the rats and improve the symptoms of vertigo. The Chinese medicine raw materials are inexpensive and have little toxic and side effects. The composition can replace the clinical application of sibelium in the treatment of posterior circulation ischemic vertigo. Although the components of the formula of the present invention are relatively common Chinese medicines and seem to have nothing special, the present invention only uses two Chinese medicines to achieve the therapeutic effect of positive drugs currently on the market. It not only has a therapeutic effect on posterior circulation ischemic vertigo, but also reduces the dosage and greatly reduces the medical cost. It has positive significance for the treatment of posterior circulation ischemic vertigo and the preparation of drugs for the treatment of posterior circulation ischemic vertigo. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0040] Figure 1 The weight changes of rats in each group before and after posterior circulation ischemic vertigo surgery were shown.
[0041] Figure 2 These are the test results of blood flow changes in each group of rats before and after 4 weeks of treatment with the Chinese medicine composition. DETAILED DESCRIPTION
[0042] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.
[0043] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.
[0044] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.
[0045] The overall idea of the present invention is as follows:
[0046] Posterior circulation ischemia (PCI) belongs to the category of "vertigo" in traditional Chinese medicine. Its name was first seen in the "Inner Canon of Medicine". There are also names such as "vertigo, dizziness, and dizziness". The cause of this disease is mainly due to the academic view of wind (fire), phlegm, stasis and deficiency. Its location is in the head and is closely related to the kidney, liver and spleen. The clinical symptoms are mainly phlegm turbidity blocking the middle, qi and blood deficiency, qi deficiency and blood stasis and liver yang hyperactivity. The inventor believes that the elderly are due to kidney qi deficiency. The kidney is the root of the human body's yang. Kidney failure means that the human body's yang is insufficient, so qi deficiency cannot circulate blood, blood circulation is not smooth, and stasis is blocked inside; the kidney is responsible for bone and marrow production. Kidney deficiency means that the sea of marrow is insufficient, and the sea of marrow is malnourished, resulting in vertigo. Elderly people often show symptoms of kidney deficiency and blood stasis. Therefore, the present invention starts from "warming yang and tonifying the kidney, promoting blood circulation, removing blood stasis and unblocking meridians", and obtains a Chinese medicine composition by studying the reasonable ratio and synergistic effect of each medicinal material component. It is the first time to propose that Epimedium is the main medicine and Chuanxiong is the auxiliary medicine, and an independent prescription is used for the treatment of posterior circulation ischemic vertigo. It has positive significance for the treatment of posterior circulation ischemic vertigo and the preparation of drugs for the treatment of posterior circulation ischemic vertigo.
[0047] The Chinese medicine composition of the present invention uses Epimedium as the main drug, which can warm and nourish kidney yang, nourish the kidney and replenish essence, produce essence and marrow to the brain, nourish the brain marrow, wake up the brain and open the mind; Chuanxiong is the auxiliary drug, which is known as the "blood-qi medicine", can both promote blood circulation and remove blood stasis, and can promote qi and stop bleeding, and has the effect of promoting the flow of qi and blood. The medicine can also "go up to the head" to treat the symptoms of blood stasis in the head. The combination of the two can play a synergistic role and increase the effects of "warming yang and tonifying the kidney, promoting blood circulation and removing blood stasis and unblocking meridians", thereby achieving the treatment of posterior circulation ischemic vertigo.
[0048] The present invention constructs a rat model of posterior circulation ischemic vertigo and observes the obvious improvement of the above-mentioned Chinese medicine composition on rat cerebral blood rheology and vertigo, which can confirm that the Chinese medicine composition proposed by the present invention can effectively increase the cerebral blood flow velocity of rats with posterior circulation ischemic vertigo and improve the symptoms of vertigo, and the Chinese medicine raw materials used are low in price and have little toxic and side effects. The Chinese medicine composition of the present invention is very promising in the preparation of drugs for treating posterior circulation ischemic vertigo, and has positive practical significance in the field of treatment of posterior circulation ischemic vertigo.
[0049] In addition, the Chinese medicine composition of the present invention can be used not only to treat posterior circulation ischemic vertigo, but also to treat other ischemic vertigo diseases, including cervical vertigo, and is extremely universal.
[0050] The following will describe in detail the Chinese medicine composition, Chinese medicine extract and application thereof for treating posterior circulation ischemic vertigo in combination with the embodiments and experimental data.
[0051] In the following embodiments of the present invention, unilateral carotid artery and subclavian artery ligation is a common ischemic vertigo animal model in the field at home and abroad. Experimental methods not specifically marked, namely, the platform test and laser speckle blood flow meter detection, are common experimental methods in the field.
[0052] Example 1
[0053] The present embodiment provides a Chinese medicinal composition for treating posterior circulation ischemic vertigo, comprising the following components by weight: 48 g of Epimedium and 36 g of Ligusticum chuanxiong.
[0054] The present embodiment provides a Chinese medicine extract liquid for treating posterior circulation ischemic vertigo, which is prepared by the following steps:
[0055] Epimedium 48g, Chuanxiong 36g, total 84g, add 15 times the amount of water, without soaking, reflux extraction for 1h, extract twice, and combine the two filtrates. Concentrate under reduced pressure at 70℃ to obtain a concentrate, spray dry the concentrate to obtain a dry paste powder. Weigh an appropriate amount of dry paste powder, add purified water to prepare a 0.433g crude drug / mL Xingnao Fang water extract for administration.
[0056] This embodiment also prepares an oral liquid, granules and tablets for treating posterior circulation ischemic vertigo, as follows:
[0057] The oral liquid is prepared by a method comprising the following steps: taking the raw material of the Chinese medicine compound, adding 15 times the amount of water, without soaking, and reflux extraction twice, each time for 1 hour, to prepare a water extract of the Xingnao formula; concentrating the water extract under reduced pressure at 50-70°C to obtain a concentrated solution, and then spray drying and sieving to obtain an extract powder; taking an appropriate amount of water, boiling it, then adding the intermediate, stirring, boiling for 10 minutes, refrigerating for 24 hours, centrifuging (10000r / min, 10 minutes), taking the centrifuged liquid, stirring it evenly, filling it, and sterilizing it (100°C, 30 minutes) to obtain the Xingnao oral liquid.
[0058] The granules are prepared by a method comprising the following steps: taking the raw material of the Chinese medicine compound, adding 15 times the amount of water, without soaking, and reflux extraction twice, each time for 1 hour, to prepare a water extract of Xingnao Fang; concentrating the water extract under reduced pressure at 50-70°C to obtain a concentrated solution, and then spray drying and sieving to obtain an extract powder; mixing the extract powder and dextrin evenly, and granulating by a dry method to obtain the granules.
[0059] The tablet is prepared by a method comprising the following steps: taking the raw material of the Chinese medicine compound, adding 15 times the amount of water, without soaking, reflux extraction twice, each time for 1 hour, concentrating the water extract under reduced pressure at 70°C to obtain an extract, spray drying to obtain a dry paste powder, adding a filler (the filler is microcrystalline cellulose, lactose, etc.) to the dry paste powder, and further adding a 5% main drug amount of a disintegrant (for example, the disintegrant is PVPP:CWS-Na), adding a binder (for example, 3% PVP K30 prepared with 85% ethanol), a wetting agent (such as 85% ethanol), granulating, drying, granulating, and finally adding a lubricant (for example, magnesium stearate, 0.6% of the amount of the particles), pressing into tablets, and obtaining the tablet.
[0060] Comparative Example 1
[0061] The difference between Comparative Example 1 and Example 1 is that: Epimedium is removed from the Chinese medicine composition and replaced with 12 g of Morinda officinalis; the preparation method of the Chinese medicine extract is the same as that of Example 1.
[0062] Comparative Example 2
[0063] The difference between Comparative Example 2 and Example 1 is that: Chuanxiong is removed from the traditional Chinese medicine composition and replaced with 9 g of Salvia miltiorrhiza; the preparation method of the traditional Chinese medicine extract is the same as that of Example 1.
[0064] Comparative Example 3
[0065] The difference between Comparative Example 3 and Example 1 is that: the Chinese medicine composition contains 9g of Epimedium and 9g of Ligusticum chuanxiong; and the preparation method of the Chinese medicine extract is the same as that of Example 1.
[0066] Example 2
[0067] This example evaluates the efficacy of the Chinese herbal extracts prepared in Example 1 and Comparative Examples 1-3 in treating posterior circulation ischemic vertigo.
[0068] 1. Establishment of ischemic vertigo rat model:
[0069] 6-8 weeks old SD rats, half male and half female, weighing 160-180g, were selected for the experiment after adaptive feeding for one week. The rat model of ischemic vertigo was established. The specific method was as follows: the rats were anesthetized with 10% chloral hydrate at 3.5mL / kg according to their body weight, fixed in the supine position, the neck skin was cut open, the muscles were bluntly separated, the right common carotid artery was exposed and separated, and ligated with thread; the right common carotid artery was traced along the right common carotid artery to the bifurcation with the right subclavian artery in the chest cavity, the right subclavian artery was hooked out, ligated with thread, and then the skin was sutured in turn, and disinfected. The rats in the control group were not treated.
[0070] 2. Intervention of rats with ischemic vertigo:
[0071] After the modeling was completed, the rats were divided into a model group, a low-dose group of Chinese medicine composition, a medium-dose group of Chinese medicine composition, a high-dose group of Chinese medicine composition, a flunarizine hydrochloride group (Western medicine positive control drug) and a xuanyunning (Chinese medicine positive control drug) group. The low-, medium- and high-dose groups of Chinese medicine composition were infused with different concentrations of the Chinese medicine extract obtained in Example 1, and the rats were gavaged at 5.6 mg / kg, 11.2 mg / kg and 22.4 mg / kg according to the weight of the rats; the rats in the flunarizine hydrochloride group were gavaged at 24 mg / kg; the rats were gavaged at 0.31 g / kg; the control group and the model group were gavaged with the same amount of normal saline, 1 time / d, and continuously administered for 14 days. The follow-up experiment was carried out 24 hours after the last administration. At the same time, the Chinese medicine extract gavage group obtained in comparative examples 1 to 3 was added, and the dosage was 11.2 mg / kg. All groups were divided into 10 groups, half male and half female.
[0072] 3. Jumping platform experiment
[0073] Three days before modeling, the jumping platform test was performed continuously. The rats were placed in the jumping platform recorder. After acclimation for 3 minutes, they were electrically stimulated at 30V, 50Hz for 5 minutes. The training was successful if the rat jumped onto the platform and remained on the platform for 30 seconds. Four weeks after modeling, the experiment was started 24 hours after the last medication. The rats were placed in a centrifuge and rotated at a constant speed of 500r / min for 30 seconds, then stopped and immediately placed in the jumping platform recorder. The time from the rat receiving electrical stimulation to the first jump onto the platform and not falling within 30 seconds was recorded as the incubation period.
[0074] 4. Laser speckle blood flowmeter detection
[0075] Before and after modeling, a brain stereotaxic instrument was used to fix the rat's head, and the hair on the rat's head was removed near the front of the ear in the middle of the head. The rat was disinfected with iodine and the skin on the top of the head was cut about 1.5-2.0 cm with ophthalmic scissors. The length of the anterior bregma and the lambdoid point of the head was used as the length, and the cerebral cortical blood flow with a width of about 0.5 cm on the left and right of the line connecting the two points was used as the observation range. The skull was thinned with a cranial drill, and the best observation thickness was that the blood vessels could be seen through the skull with the naked eye. A cotton ball was dipped in 0.9% saline and gently applied to the exposed skull. Laser speckle contrast imaging was performed to record the cerebral blood flow change image. The image was analyzed using SIM BFISoftware off line software, and a circular area was taken to calculate the average value of the area within 15 seconds as the final cerebral blood flow change value.
[0076] 5. Safety evaluation
[0077] 0.5-1 ml of blood was collected from the abdominal aorta of rats, placed in a test tube containing 10-20 μl of EDTA-K2 (concentration 15%) anticoagulant, shaken, and measured using a BAYER ADVIA 120 five-differential blood cell analyzer to measure blood parameters: red blood cell count (RBC), hemoglobin (HGB), white blood cell count (WBC), red blood cell volume (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet count (PLT), reticulocyte percentage (%RETIC), neutrophil percentage (%NEUT), lymphocyte percentage (%LYMPH), monocyte percentage (%MONO), eosinophil percentage (%EOS), and basophil percentage (%BASO).
[0078] About 3 ml of blood was collected from the abdominal aorta and centrifuged at 3000 rpm for 15 minutes. The serum was taken for blood biochemistry examination using Hitachi 7080 fully automatic biochemical analyzer. The test indicators included aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), urea nitrogen (BUN), creatinine (CREAT), total protein (TP), albumin (ALB), blood glucose (GLU), total bilirubin (TB), total cholesterol (CHOLT), triglyceride (TG), and creatine kinase (CK). Sodium, potassium, and chloride ions were determined using an XD683 ion analyzer.
[0079] Observe whether there are any deaths, record the number of deaths, and conduct timely autopsies to understand the cause of death.
[0080] 6. The test results are as follows:
[0081] 6.1 Effect of Chinese herbal medicine combination on vertigo in rats with ischemic vertigo
[0082] The results showed that compared with the control group, the platform jumping latency of the rats in the model group was significantly prolonged (P<0.05); compared with the model group, the platform jumping escape latency of the ischemic vertigo rats in the low, medium and high dose groups of the composition of Example 1 was significantly shortened and in a dose-dependent manner (p<0.05), as shown in Table 1.
[0083] Table 1 The escape latency of ischemic vertigo rats in different treatment groups
[0084]
[0085]
[0086] Compared with the control group, ## p<0.01; compared with the model group, * p<0.05, ** p<0.01.
[0087] 6.2 Effect of Chinese herbal medicine combination on improving cerebral blood flow in rats with ischemic vertigo
[0088] The results showed that before and after modeling, there was a significant difference in the changes in cerebral blood flow between the control group and the model group (P<0.01). After drug intervention, the improvement in cerebral blood flow velocity of rats in the low, medium and high dose groups of the composition of Example 1 was dose-dependent. The cerebral blood flow values of rats in the medium and high dose groups of the composition of Example 1 were similar to those of the positive drugs flunarizine hydrochloride and xuanningning, and the difference was not statistically significant. Figure 2 .
[0089] As shown in Table 2, from the data of Comparative Examples 1 to 2, it can be seen that Salvia miltiorrhiza and Morinda officinalis also have a certain impact on the therapeutic effect, but the improvement of vertigo is not obvious.
[0090] Table 2 Comparison of the improvement of cerebral blood flow perfusion and platform escape latency in rats with ischemic vertigo by different treatment methods ( N=6)
[0091]
[0092] 6.3 Safety evaluation
[0093] During the administration period, the rats were in good mental state, with normal behavior and breathing, no abnormal secretion of salivary glands, lacrimal glands and other glands, smooth fur, and no abnormality in feces and urine. There were no significant differences in the various indicators of the high, medium and low dose groups of the Chinese medicine composition of Example 1 compared with the control group. The results are shown in Tables 3 and 4.
[0094] Table 3 Hematological examination of rats taking Chinese herbal extracts for one month ( N=6)
[0095]
[0096]
[0097] Table 4 Blood biochemical examination of rats taking Chinese herbal extracts for one month ( N=6)
[0098]
[0099] The body weights of the rats in each group were tested before surgery and at 2, 3, and 4 weeks after surgery. Figure 1 As shown in Tables 3, 4 and Figure 1 It can be seen that the Chinese medicine composition of the present invention has the advantage of high safety.
[0100] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.
[0101] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0102] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. A Chinese medicine composition for treating posterior circulation ischemic vertigo, characterized in that: The traditional Chinese medicine composition consists of epimedium and chuanxiong, wherein the mass ratio of epimedium to chuanxiong is 4:
3.
2. A Chinese medicinal extract for treating posterior circulation ischemic vertigo, characterized in that: The Chinese medicine extract is an extract of the Chinese medicine composition for treating posterior circulation ischemic vertigo as described in claim 1.
3. The method for preparing a Chinese medicinal extract for treating posterior circulation ischemic vertigo according to claim 2, characterized in that: The preparation method comprises: Mixing the Chinese medicinal composition for treating posterior circulation ischemic vertigo according to claim 1 with water to obtain a mixture; The mixture is subjected to heating reflux extraction and reduced pressure concentration to obtain a water extract concentrate; The water extract concentrate is dried to obtain a Chinese medicinal extract for treating posterior circulation ischemic vertigo.
4. The method for preparing a Chinese medicinal extract for treating posterior circulation ischemic vertigo according to claim 3, characterized in that: The Chinese medicine composition for treating posterior circulation ischemic vertigo according to claim 1 is mixed with water to obtain a mixture, which specifically comprises: Mixing the Chinese medicinal composition for treating posterior circulation ischemic vertigo according to claim 1 with 15 times the amount of water to obtain a mixture; The mixture is subjected to heating reflux extraction and reduced pressure concentration to obtain a water-extracted concentrated solution, which specifically comprises: The mixture was heated and refluxed for extraction twice, each time for 1 hour, to obtain the Xingnao Fang water extract; Concentrating the water extract of the Xingnao Recipe under reduced pressure at 50-70° C. to obtain a water extract concentrate; Among them, the specific gravity of the water-extracted concentrate is 1.10-1.
20.
5. The method for preparing a Chinese medicinal extract for treating posterior circulation ischemic vertigo according to claim 3, characterized in that: The water extract concentrate is dried to obtain a Chinese medicine extract for treating posterior circulation ischemic vertigo, which specifically comprises: spray-drying the water extract concentrate to obtain a Chinese medicinal extract for treating posterior circulation ischemic vertigo; The spray drying temperature is 110-120°C.
6. Use of a Chinese medicine composition for treating posterior circulation ischemic vertigo as claimed in claim 1 in preparing a drug for preventing and treating posterior circulation ischemia or posterior circulation ischemic vertigo.
7. Use of the Chinese medicinal extract for treating posterior circulation ischemic vertigo as claimed in claim 2 in the preparation of a drug for preventing and treating posterior circulation ischemia or posterior circulation ischemic vertigo.
8. Use of the Chinese medicine composition for treating posterior circulation ischemic vertigo as claimed in claim 1 in the preparation of drugs for preventing and treating ischemic vertigo.
9. Use of the Chinese medicinal extract for treating posterior circulation ischemic vertigo as claimed in claim 2 in the preparation of a drug for preventing and treating ischemic vertigo.
10. A drug for preventing and treating posterior circulation ischemia or posterior circulation ischemic vertigo, characterized in that: The active ingredients of the medicine include the Chinese medicine composition for treating posterior circulation ischemic vertigo as described in claim 1 and / or the Chinese medicine extract for treating posterior circulation ischemic vertigo as described in claim 2.
11. The drug for preventing and treating posterior circulation ischemia or posterior circulation ischemic vertigo according to claim 10, characterized in that: The drug further comprises pharmaceutically acceptable excipients, which include at least one of excipients, carriers, binders and lubricants.
12. The drug for preventing and treating posterior circulation ischemia or posterior circulation ischemic vertigo according to claim 10, characterized in that: The dosage form of the drug includes any one of granules, oral liquid, tablets and capsules.
13. A drug for preventing and treating ischemic vertigo, characterized in that: The active ingredients of the medicine include the Chinese medicine composition for treating posterior circulation ischemic vertigo as described in claim 1 and / or the Chinese medicine extract for treating posterior circulation ischemic vertigo as described in claim 2.
14. A drug for preventing and treating ischemic vertigo according to claim 13, characterized in that: The medicine for preventing and treating ischemic vertigo includes a medicine for preventing and treating cervical vertigo.
Citation Information
Patent Citations
Traditional Chinese medicine composition for treating vascular dementia
CN102552365A
Nattokinase composition and preparation method thereof
CN106039296A
Chinese medicine possessing kidney supplementing brain fortifying, statis transforming and vessel freeing actions
CN1442190A
